GSDME and oral cavity squamous cell carcinoma: In oral squamous cell carcinoma, decitabine combined with cisplatin and immune-checkpoint inhibitors can amplify the immunotherapies outcomes, and the activation of GSDME can improve the sensitivity of chemotherapeutics and activate inflammatory tumour-cell pyroptosis [41].